# Can treatment with N-PEP-12 improve recovery after acute ischemic stroke?

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
11/02/2019		[X] Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
19/02/2019		[X] Results		
<b>Last Edited</b> 28/06/2024	Condition category Circulatory System	[] Individual participant data		

### Plain English summary of protocol

Background and study aims

Impairment of mental (cognitive) processing is a common finding in patients with stroke, regardless of severity, and it has an important impact on quality of life. This is a pilot study to investigate the effects of N-Pep-12 treatment on the recovery of patients with post-stroke cognitive impairment. N-Pep-12 is a proprietary, peptide-based nutritional supplement that has been shown to exert neuroprotective and pro-cognitive effects in experimental studies as well as in earlier clinical studies in patients suffering from age-related cognitive deficits.

### Who can participate?

Adults between 18 and 80 years with supratentorial ischemic stroke onset 30-120 days prior to screening.

#### What does the study involve?

Participants are invited to join this study at 30-120 days post stroke onset. After informing patients about study procedures, benefits and potential risks, they sign a consent form. All participants included in the study must pass the screening criteria and baseline evaluations. Individuals are then allocated to one of two groups. The first group is administered N-Pep-12 (90 mg) capsules, once per day, oral, for 90 days, while the second group doesn't get any treatment.

### What are the possible benefits and risks of participating?

Potential benefit of N-Pep-12 administration is the improved cognitive function and brain recovery in patients with post-stroke cognitive impairment. The main risk for patients is developing adverse events (AE). Their severity and the causality to study medication is carefully assessed in order to establish a detailed safety profile of the intervention.

#### Where is the study run from?

The N-PEP-12 is a single centre trial run from Cluj-Napoca, Romania.

When has the study started and how long is it expected to run for? April 2016 to September 2019

### Who is funding the study?

The Society for the Study of Neuroprotection and Neuroplasticity (SSNN) (Romania)

Who is the main contact?

- 1. Prof. Dr. Dafin Fior Muresanu, dafinm@ssnn.ro
- 2. Stefan Strilciuc, MPH, stefan.strilciuc@ssnn.ro

### Contact information

### Type(s)

Scientific

#### Contact name

Prof Dafin Muresanu

#### **ORCID ID**

http://orcid.org/0000-0002-9536-1153

#### Contact details

No. 37 Mircea Eliade Street Cluj-Napoca Romania 400364 +40740066761 dafinm@ssnn.ro

### Type(s)

Public

#### Contact name

Mr Stefan Strilciuc

#### **ORCID ID**

http://orcid.org/0000-0001-6112-0223

#### Contact details

No. 37 Mircea Eliade street Cluj-Napoca Romania 400364 +40740066761 stefan.strilciuc@ssnn.ro

# Additional identifiers

### **EudraCT/CTIS** number

Nil known

#### IRAS number

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

Nil known

# Study information

#### Scientific Title

Combined Neuropsychological, Neurophysiological and Psychophysiological Assessment of the Effects of N-Pep-12 on Neurorecovery in Patients after Ischemic Stroke

### Acronym

N-Pep-12

### **Study objectives**

The study assesses the therapeutic effect and the safety of a single daily dose of 90 mg of N-Pep-12 in supporting neurorecovery in comparison to a control group of patients after stroke

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 10/12/2015, Ethics Committee of the Iuliu Hatieganu University of Medicine and Pharmacy (8 Babeş Street, 400012 Cluj-Napoca, Romania; +40-264-597-256; contact@umfcluj.ro), ref: 507/10.12.2015. Amended twice refs: 82/24.03.2016;104/12.02.2018

### Study design

Exploratory, prospective, randomized, single-blinded, controlled study

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

No participant information sheet available

### Health condition(s) or problem(s) studied

Supratentorial, radiologically confirmed ischemic stroke with the onset 30-120 days prior to screening

#### **Interventions**

The synopsis of the study is organised in 3 visits:

Visit 1 – Screening / Baseline

Visit 2 – Efficacy / Safety - Day 30

Visit 3 – Efficacy / Safety - Day 90

No follow-up was performed after the 90-day evaluation. The study arms were administered the following treatment courses:

1. Treatment Group:

N-Pep-12 (90 mg) capsules 1/ day oral for 90 days

2. Reference Group

Randomisation, Blinding and Unblinding

This is a single-blinded study. Communication is forbidden between assessments and the person who gives the treatment.

Patients meeting the inclusion and exclusion criteria will be randomly assigned to receive either active treatment or control treatment based on the time of their enrollment in the study. Randomisation was performed 2:1 (2 -intervention, 1 -placebo). The first two patients enrolled will receive active treatment, the third patient will receive placebo. This allocation scheme shall be continued until 120 patients have been enrolled.

### **Intervention Type**

Drug

#### Phase

Phase IV

### Drug/device/biological/vaccine name(s)

N-PEP-12

### Primary outcome measure

- 1. Cognitive function assessed using Montreal Cognitive Assessment (MoCA) (Nasreddine, 2005) at days 0, 30, 90
- 2. Emotional status assessed using Hospital Anxiety and Depression Scale (Zigmond, 1983) at days 0, 30, 90
- 3. Cognitive function assessed using Digit Span (Wechsler adult intelligence scale third edition (Wechsler, 1997) at days 0, 30, 90
- 4. Cognitive function assessed using Color Trails Test (Posch, 2005) at days 0, 30, 90
- 5. Cognitive function assessed using PSI (Processing Speed Index, Wechsler adult intelligence scale third edition) at days 0, 30, 90

### Secondary outcome measures

Current secondary outcome measures as of 02/04/2020:

- 1. Eye movements assessed using a Tobii Pro TX300 eye tracking device and analyzed using Tobii Studio software at days 0, 30, 90
- 2. Brain electrical activity assessed using electoencephalography (EEG) and analyzed quantitatively using BrainAnalyzer software at days 0, 30, 90

Previous secondary outcome measures:

1. Eye movements assessed using a Tobii Pro TX300 eye tracking device and analyzed using Tobii

Studio software at 30, 101 and 180 days

2. Brain electrical activity assessed using electoencephalography (EEG) and analyzed quantitatively using BrainAnalyzer software at 30, 101 and 180 days

### Overall study start date

01/09/2015

#### Completion date

26/10/2019

# **Eligibility**

### Key inclusion criteria

- 1. Stroke onset 30-120 days prior to screening
- 2. Stroke is ischemic in origin, supratentorial, and radiologically confirmed (CT or MRI)
- 3. No significant pre-stroke disability (pre-stroke Modified Rankin Score of 0 or 1)
- 4. Goodglass and Kaplan Communication Scale Score of > 2 at screening
- 5. No other stroke in the 3 months preceding index stroke
- 6. Age between 18 and 80 years, inclusive

### Participant type(s)

Patient

### Age group

Adult

### Lower age limit

18 Years

#### Sex

Both

### Target number of participants

120

#### Total final enrolment

121

#### Key exclusion criteria

- 1. Pre-existing and active major neurological disease
- 2. Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia (the short Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score >3)
- 3. Advanced liver, kidney, cardiac, or pulmonary disease
- 4. A terminal medical diagnosis consistent with survival < 1 year
- 5. Major drug dependency, including alcohol (in the investigator's judgment).
- 6. Injury of writing hand influencing cognitive or other outcome measures, in the investigator's judgment.
- 7. Females who are pregnant or lactating.
- 8. Hemianopsia

9. Neglect 10. Myopia >3 11. Glaucoma

### Date of first enrolment

05/04/2016

Date of final enrolment

26/07/2019

### Locations

#### Countries of recruitment

Romania

# Study participating centre RoNeuro Institute for Neurological Research and Diagnostic

No. 37 Mircea Eliade Street Cluj-Napoca Romania 400364

# Sponsor information

### Organisation

EN: The foundation for the study of neuroscience and neuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)

### Sponsor details

No. 37 Mircea Eliade Street Cluj-Napoca Romania 400364 +40740150076 office@ssnn.ro

#### Sponsor type

Research organisation

# Funder(s)

### Funder type

Research organisation

#### Funder Name

EN: The foundation for the study of neuroscience and neuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)

### **Results and Publications**

### Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

### Intention to publish date

31/12/2020

### Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### **Study outputs**

Output type Details		Date created	Date added	Peer reviewed?	Patient- facing?
<u>Results</u> <u>article</u>	results	02/10 /2020	02/12 /2020	Yes	No
Results article		01/06 /2021	28/06 /2021	Yes	No
Other publications	Correlating Eye-Tracking Fixation Metrics and Neuropsychological Assessment after Ischemic Stroke	25/07 /2023	05/03 /2024	Yes	No
<u>Protocol file</u>	version 2.0	17/01 /2018	28/06 /2024	No	No